TIDMFIPP
RNS Number : 9898S
Frontier IP Group plc
15 March 2023
15 March 2023
Frontier IP Group plc
("Frontier IP", the "Group" or the "Company")
Board changes
Frontier IP (AIM:FIPP), a specialist in commercialising
intellectual property, announces:
-- the appointment of Nigel Grierson and Dr David Holbrook as
independent Non-Executive Directors with effect from 15 March
2023.
-- the appointment of Professor Dame Julia King, Baroness Brown
of Cambridge, DBE FREng FRS FMedSci, currently an independent
Non-Executive Director, as Senior Independent Director with effect
from 15 March 2023.
-- that Dr Campbell Wilson, currently a Non-Executive Director,
has notified the Group that he has decided to step down from his
non-executive role at Frontier IP during April 2023 having served
on the Board for nearly nine years.
Nigel Grierson has 20 years' operating experience in the IT
industry with positions in product development, marketing, and
senior management, and, as Managing Director of venture capital
funds managing investments of over $500 million in 70 technology
start-up companies across Europe. Nigel's early career was in
product development; designing semiconductors for the telecom
industry, process control systems for the automotive industry, and
navigation/telemetry systems for the offshore oil exploration
industry.
Nigel was a co-Managing Director of the Doughty Hanson
Technology Fund, established in 2000, which was part of Doughty
Hanson Private Equity Partners. Between 1984 and 2000, he held
senior roles at Intel Corporation between becoming Co-Director EMEA
for Intel Capital Group, developing and leading a team to establish
Intel as a leading corporate technology investor. Nigel ran
strategic programmes working directly for Intel's then Chief
Executive Officer Dr Andrew Grove and Chief Operating Officer Dr
Craig Barrett. Nigel is FCA qualified to run controlled functions
and is an alumnus of the INSEAD Fontainbleau Advanced Management
Program.
Dr David Holbrook is a leading healthcare technology investment
professional with 30 years' experience in the life sciences
sectors. He has sat on more than 20 boards of directors during his
career. David is currently a non-executive director at AIM quoted
Oxford BioDynamics plc, where he also chairs the audit committee.
He is also a senior advisor to digital health investor RYSE Asset
Management and Chairman of The Liver Group Charity based at The
Royal Free Hospital. David was also previously a General
Partner/Venture Partner for MTI Ventures LLP. David has a 40 year
history in the healthcare space, firstly as a physician and then in
senior business development roles with Glaxo, Roche and in biotech.
He has spent the last 25 years specialising in the innovation space
with much of that time in seed venture investing focused primarily
on university spin outs.
David was also senior independent director, audit committee
member and chair of the nominations committee to The Worldwide
Healthcare Trust plc, a leading investment trust. He also spent
three years establishing and managing the inaugural seed fund at
LifeArc. David has degrees from Oxford (English), King's London
(Medicine) and Harvard (MBA).
David and Nigel will both join the Company's audit and
remuneration committees on appointment and David will become Chair
of the audit committee.
Dame Julia King, Baroness Brown of Cambridge, joined the
Frontier IP Board of Directors in October 2021 as an independent
Non-Executive Director and will, with effect from today following
the appointments of Nigel and David, assume the role of Senior
Independent Director on the board.
The Company also announces that Dr Campbell Wilson, currently a
Non-Executive Director, has notified the Group that, having served
on the Board for nearly nine years, he has decided to step down
from his non-executive role at Frontier IP. Campbell will be
stepping down from the board of Frontier IP in April 2023, but will
continue to support the Group in an advisory capacity with selected
portfolio companies.
Neil Crabb, Chief Executive Officer of Frontier IP Group plc,
commented:
"I am delighted to welcome Nigel and David to our Board of
Directors. Their extensive experience in technologies across
sectors such as semiconductors and life sciences, and in working
with early-stage technology companies will prove invaluable to the
Group as commercialise and scale up our portfolio companies.
I would also very much like to thank Campbell for his support
over the past nine years. His role has proved vital to helping us
develop, and I am delighted that he will continue to be involved
with the Group once he has stepped down from the Board."
Further regulatory disclosures
The following additional information is provided in accordance
with Rule 17 and Schedule Two Paragraph (g) of the AIM Rules for
Companies.
David Mark Anthony Holbrook, age 62, owns no ordinary shares in
the Company and is, or has during the last five years, been a
director or partner of the following companies and
partnerships:
Current Directorships or Previous Directorships or
Partnerships Partnerships
Oxford BioDynamics plc Eykona Medical Limited
MTI UPF Coinvest SLP Worldwide Healthcare Trust
The Liver Group Charity plc
Ikarovec Limited
Ducentis Biotheraputics Limited
Gyreox Limited
David Holbrook was a director of Eykona Medical Limited, which
went into creditors' voluntary liquidation on 10 December 2013. The
company was dissolved on 14 May 2018 with a deficiency to unsecured
creditors of approximately GBP1.79 million.
Nigel Peter Grierson, age 67, owns no ordinary shares in the
Company and is, or has during the last five years, been a director
or partner of the following companies and partnerships:
Current Directorships or Previous Directorships or
Partnerships Partnerships
Westlecot Business Consultants None
Westlecot Holme Management
Company
Nigel Grierson was a director of Deepstream Technologies Limited
from 17 March 2004 to 30 June 2010. Deepstream Technologies Limited
entered administration on 12 June 2009. Deepstream Technologies
Limited was liquidated 15 March 2011. The estimated deficiency to
creditors as at 10 December 2010 was GBP826,274.
Enquiries
Frontier IP Group Plc T: 020 3968 7815
Neil Crabb, Chief Executive neil@frontierip.co.uk
Andrew Johnson, Communications and Investor M: 07464 546 025
Relations
andrew.johnson@frontierip.co.uk
Company website: www.frontierip.co.uk
Allenby Capital Limited (Nominated Adviser) T: 0203 328 5656
Nick Athanas / George Payne
Singer Capital Markets (Broker) T: 0207 496 3000
Sandy Fraser / Harry Gooden / George Tzimas
ABOUT FRONTIER IP
Frontier IP unites science and commerce by identifying strong
intellectual property and accelerating its development through a
range of commercialisation services. A critical part of the Group's
work is involving relevant industry partners at an early stage of
development to ensure technology meets real world demands and
needs.
The Group looks to build and grow a portfolio of equity stakes
and licence income by taking an active involvement in spin-out
companies, including support for fund raising and collaboration
with relevant industry partners at an early stage of
development.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAJIMTTMTIBTRJ
(END) Dow Jones Newswires
March 15, 2023 03:00 ET (07:00 GMT)
Frontier IP (AQSE:FIPP.GB)
Historical Stock Chart
From Dec 2024 to Jan 2025
Frontier IP (AQSE:FIPP.GB)
Historical Stock Chart
From Jan 2024 to Jan 2025
